A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01554696
Recruitment Status : Completed
First Posted : March 15, 2012
Last Update Posted : December 16, 2014
Information provided by (Responsible Party):
Astellas Pharma Inc

Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of ASP015K in moderate to severe rheumatoid arthritis subjects who are methotrexate-inadequate responders (MTX-IR).

Condition or disease Intervention/treatment Phase
Arthritis, Rheumatoid Drug: ASP015K Drug: Placebo Phase 2

Detailed Description:
Subjects in each treatment group will continue to take their concomitant oral weekly dose of methotrexate (MTX) in addition to daily ASP015K or matching placebo, taken orally with food, daily for 12 weeks after randomization.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 379 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate
Study Start Date : June 2012
Actual Primary Completion Date : February 2014
Actual Study Completion Date : February 2014

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: ASP015K lowest dose
ASP015K lowest dose daily in addition to concomitant weekly oral methotrexate
Drug: ASP015K
Experimental: ASP015K low dose
ASP015K low dose daily in addition to concomitant weekly oral methotrexate
Drug: ASP015K
Experimental: ASP015K medium dose
ASP015K medium dose daily in addition to concomitant weekly oral methotrexate
Drug: ASP015K
Experimental: ASP015K high dose
ASP015K high dose daily in addition to concomitant weekly oral methotrexate
Drug: ASP015K
Placebo Comparator: Placebo
Placebo daily in addition to concomitant weekly oral methotrexate
Drug: Placebo

Primary Outcome Measures :
  1. Percentage of subjects achieving American College of Rheumatology Criteria 20 (ACR 20) response [ Time Frame: Week 12 ]
  2. Trough plasma concentration of ASP015K and metabolite(s) [ Time Frame: up to Week 12 ]

Secondary Outcome Measures :
  1. Percentage of subjects achieving ACR 50 response [ Time Frame: Week 12 ]
  2. Percentage of subjects achieving ACR 70 response [ Time Frame: Week 12 ]
  3. Change from baseline in Disease Activity Score using 28 joint count and C Reactive Protein (DAS28-CRP) [ Time Frame: Baseline and Week 12 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject has rheumatoid arthritis (RA) diagnosed according to the 1987 revised ACR criteria for at least 6 months prior to Screening
  • Subject has been treated with oral methotrexate (MTX) for a minimum of 90 days and at a stable dose for 28 days prior to the first dose of study drug
  • ≥6 tender/painful joints; ≥6 swollen joints
  • Subject meets the ACR 1991 Revised Criteria for Global Functional Status in RA Class I, II or III at Screening and Baseline
  • Subject's other medication taken for treatment of RA must be stable for at least 28 days prior to start of the study
  • Male and female subjects must be willing to comply with contraception requirements as well as restrictions regarding egg and sperm donation
  • Female subject must not be breastfeeding at Screening or during the study period, and for 60 days after the final study drug administration
  • Subject agrees not to participate in another interventional study while on treatment

Exclusion Criteria:

  • Positive Mycobacterium tuberculosis (TB) test within 90 days of Screening
  • Abnormal chest x-ray indicative of an acute or chronic infectious process or malignancy
  • Receipt of live or live attenuated virus vaccination within 30 days prior to the first dose of study drug
  • Known history of positive test for hepatitis B surface antigen (HBsAg) or hepatitis C antibody or history of a positive test for human immunodeficiency virus (HIV) infection
  • History of any other autoimmune rheumatic disease, other than Sjogren's syndrome
  • Previous history of clinically significant infections or illness (requiring hospitalization or requiring parenteral therapy) within 90 days of the Baseline visit, or a history of any illness that would preclude participation in the study
  • History of any malignancy, except for successfully treated basal or squamous cell carcinoma of the skin or in-situ carcinoma of the cervix
  • Does not meet specified washout criteria for the following RA medications: gold, azathioprine, minocycline, penicillamine, etanercept, certolizumab, adalimumab, golimumab, infliximab, cyclophosphamide, and leflunomide
  • Subject has previously used a non anti-TNF biologic disease-modifying antirheumatic drug (DMARD) (e.g., anakinra, abatacept, rituximab, tocilizumab)
  • Previous intolerance to Janus kinase (JAK) inhibitors
  • Receipt of intra-articular or parenteral corticosteroid within 28 days prior to the first dose of study drug or is currently taking > 30 mg oral morphine (or narcotic equivalent) per day
  • Absolute lymphocyte count (ALC) < 750/mm3
  • Receipt of plasma exchange therapy within 60 days prior to the start of study drug
  • Receipt of any investigational agent within 30 days or 5 half-lives, whichever is longer, prior to first dose of study drug
  • Receipt of medications that are CYP3A substrates with narrow therapeutic range within 14 days prior to first dose of study drug
  • History of heart failure, defined as New York Heart Association (NYHA) grade 3 or greater
  • History of long QT syndrome or prolonged QT interval
  • Any ongoing severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac, neurological, or infectious disease, or any ongoing illness which would make the subject unsuitable for the study. This includes stomatitis, gastrointestinal ulcers, or any other condition that would preclude continued treatment with methotrexate
  • Subject has any condition possibly affecting oral absorption (e.g., gastrectomy, other malabsorption syndromes, or clinically significant diabetic gastroenteropathy)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01554696

  Hide Study Locations
United States, Alabama
Achieve Clinical Research, LLC
Birmingham, Alabama, United States, 35216
United States, California
The Talbert Group
Huntington Beach, California, United States, 92646
University of California San Diego
LaJolla, California, United States, 92093-0943
Desert Medical Advances
Palm Desert, California, United States, 92260
Pacific Arthritis Center Medical Group
Santa Maria, California, United States, 93454
United States, Colorado
Arthritis Associates of Colorado Springs
Colorado Springs, Colorado, United States, 80910
United States, Florida
Arthritis Associates
Orlando, Florida, United States, 32804
United States, Illinois
Illinois Bone & Joint
Morton Grove, Illinois, United States, 60053
Deerbrook Medical Asssociates
Vernon Hills, Illinois, United States, 60061
United States, Kentucky
Center for Arthritis and Osteoporosis
Elizabethtown, Kentucky, United States, 42701
United States, Maryland
The Center for Rheumatology and Bone Research
Wheaton, Maryland, United States, 20902
United States, North Carolina
PMG Research
Hickory, North Carolina, United States, 28602
United States, Oklahoma
Health Research of Oklahoma
Oklahoma City, Oklahoma, United States, 73103
United States, Pennsylvania
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States, 16635
Clincal Research Center of Reading
Wyomissing, Pennsylvania, United States, 19610
United States, Tennessee
Rheumatology Consultants, PLLC
Knoxville, Tennessee, United States, 37909-1907
United States, Texas
Austin Rheumatology Research PA
Austin, Texas, United States, 78705
United States, Virginia
Center for Arthritis & Rheumatic Disease, P.C.
Chesapeake, Virginia, United States, 23320
United States, West Virginia
Mountain State Clinical Research
Clarksburg, West Virginia, United States, 26301
Hospital Erasme
Brussels, Belgium, 1070
Moliere Hospital
Brussels, Belgium, 1190
MHAT Burgas
Burgas, Bulgaria, 8000
MHAT Plovdiv AD
Plovdiv, Bulgaria, 4003
MHAT "Sv. Ivan Rilski"
Sofia, Bulgaria, 1612
IPS Rodrigo Botero SAS
Medellin, Antioquia, Colombia, 5001000
Centro Integral de Reumatología del Caribe S.A.S
Barranquilla, Colombia
Centro Integral De Reumatologia E Inmunologia
Bogota, Colombia
Medicity Sas
Bucaramanga, Colombia
Servimed E.U.
Bucaramanga, Colombia
Centro de medicina Interna Julian Coronel
Cali, Colombia
Czech Republic
Revmatologicky ustav
Praha 2, Czech Republic, 128 50
Uherske Hradiste, Czech Republic, 68601
Zlin, Czech Republic, 760 01
DRC Gyogyszervizsgalo Kozpont Kft
Balatonfured, Hungary, H-8230
Rethy Pal Korhaz es Rendelointezet
Bekescsaba, Hungary, 5600
Revita Clinic Rheumatology
Budapest, Hungary, 1027
Kenezy Hospital Institute of Clinical Pharmacology
Debrecen, Hungary, H-4043
Morales Vargas Centro de Investigacion, SC Rheumatology
Leon, Guanajuato, Mexico, 37000
Hospital Civil de Guadalajara Fray Antonio Alcalde Gutierrez
Guadalajara, Mexico, 44280
Dr Javier Orozco Alcala Private Doctor´s office
Guadalajara, Mexico, 44650
Cliditer S.A. de C.V.Huerta S.I.
Mexico D.F., Mexico, 6700
Centro de Investigacion Clinica de Morelia, S.C.
Morelia, Mexico, 58070
NZOZ Osteo-Medic sc A. Racewicz, J. Supronik
Bialystok, Poland, 15-351
Centrum Osteoporozy i Chorob KKostno-Stawowych Daniluk Clinical Research Centre
Bialystok, Poland, 15-461
Szpital Uniwersytecki nr. 2 im. Dr. Jana Biziela
Bydgoszcz, Poland, 85-168
NZOZ Centrum Medyczne ProMiMed
Krakow, Poland, 31-637
Zespol Poradni Specjalistycznych REUMED sp. Zo.o
Lublin, Poland, 20-582
ARS Rheumatica
Warszawa, Poland, 02-653
Rheuma Medicus Zaktad Opieki Zdrowotnej Relle Brkolozka
Wraszawa, Poland, 02-118
Sponsors and Collaborators
Astellas Pharma Inc
Study Director: Senior Medical Director Director Astellas Pharma Global Development

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Astellas Pharma Inc Identifier: NCT01554696     History of Changes
Other Study ID Numbers: 015K-CL-RA21
2011-006018-15 ( EudraCT Number )
First Posted: March 15, 2012    Key Record Dates
Last Update Posted: December 16, 2014
Last Verified: December 2014

Keywords provided by Astellas Pharma Inc:
Rheumatoid Arthritis

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors